Elevance Health Inc Financials
Elevance Health Inc (ELV) reported $199.1B in revenue for fiscal year 2025, up 12.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Elevance’s top-line growth is being outweighed by margin compression and a sharper drop in cash conversion.
From FY2023 to FY2025, revenue expanded by roughly$27.8B , yet free cash flow fell to$3.2B ; the important shift is that added scale is arriving with less cash behind it. Earnings quality also softened because operating cash flow fell to$4.3B while net income remained$5.7B , reversing the earlier pattern of cash running ahead of accounting profit.
The business is still growing, but incremental revenue is less profitable: operating margin compressed from
Liquidity looks steady rather than strained, with a current ratio of 1.5x and cash of
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Elevance Health Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Elevance Health Inc has an operating margin of 3.6%, meaning the company retains $4 of operating profit per $100 of revenue. This results in a moderate score of 60/100, indicating healthy but not exceptional operating efficiency. This is down from 4.4% the prior year.
Elevance Health Inc's revenue grew 12.5% year-over-year to $199.1B, a solid pace of expansion. This earns a growth score of 59/100.
Elevance Health Inc has elevated debt relative to equity (D/E of 0.70), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 25/100, reflecting increased financial risk.
Elevance Health Inc's current ratio of 1.54 indicates adequate short-term liquidity, earning a score of 42/100. The company can meet its near-term obligations, though with limited headroom.
Elevance Health Inc has a free cash flow margin of 1.6%, earning a moderate score of 37/100. The company generates positive cash flow after capital investments, but with room for improvement.
Elevance Health Inc earns a strong 12.9% return on equity (ROE), meaning it generates $13 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 75/100. This is down from 14.5% the prior year.
Elevance Health Inc scores 3.14, well above the 2.99 safe threshold. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Elevance Health Inc passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Elevance Health Inc generates $0.76 in operating cash flow ($4.3B OCF vs $5.7B net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Elevance Health Inc earns $5.13 in operating income for every $1 of interest expense ($7.2B vs $1.4B). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Elevance Health Inc generated $199.1B in revenue in fiscal year 2025. This represents an increase of 12.5% from the prior year.
Elevance Health Inc's EBITDA was $8.7B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 5.5% from the prior year.
Elevance Health Inc reported $5.7B in net income in fiscal year 2025. This represents a decrease of 5.3% from the prior year.
Elevance Health Inc earned $25.21 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 1.8% from the prior year.
Cash & Balance Sheet
Elevance Health Inc generated $3.2B in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 30.3% from the prior year.
Elevance Health Inc held $9.5B in cash against $30.8B in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Elevance Health Inc's operating margin was 3.6% in fiscal year 2025, reflecting core business profitability. This is down 0.8 percentage points from the prior year.
Elevance Health Inc's net profit margin was 2.8% in fiscal year 2025, showing the share of revenue converted to profit. This is down 0.5 percentage points from the prior year.
Elevance Health Inc's ROE was 12.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 1.6 percentage points from the prior year.
Not reported for fiscal year 2025.
Capital Allocation
Elevance Health Inc spent $2.6B on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 10.2% from the prior year.
Elevance Health Inc invested $1.1B in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 11.1% from the prior year.
Not reported for fiscal year 2025.
ELV Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $201.1B | $199.1B+12.5% | $177.0B+3.3% | $171.3B+9.4% | $156.6B+13.0% | $138.6B+13.8% | $121.9B+16.9% | $104.2B+13.1% | $92.1B+2.3% | $90.0B+6.1% | $84.9B+7.2% | $79.2B+7.2% | $73.9B+4.0% | $71.0B+15.5% | $61.5B+1.3% | $60.7B |
| Cost of Revenue | $21.9B | $21.2B+7.2% | $19.8B+14.2% | $17.3B+32.7% | $13.0B+19.6% | $10.9B+21.7% | $9.0B+349.4% | $2.0B | $0 | $0 | N/A | N/A | N/A | N/A | $137.4M | $0 |
| SG&A Expenses | $22.6B | $21.0B+4.8% | $20.0B-0.3% | $20.1B+13.5% | $17.7B+11.2% | $15.9B-8.8% | $17.4B+30.6% | $13.4B-4.7% | $14.0B+10.8% | $12.7B+0.7% | $12.6B+0.2% | $12.5B+6.7% | $11.7B+18.0% | $10.0B+14.7% | $8.7B+2.9% | $8.4B |
| Operating Income | $5.5B | $7.2B-8.4% | $7.9B-7.5% | $8.5B+2.6% | $8.3B+9.6% | $7.6B+18.9% | $6.4B+6.0% | $6.0B+10.6% | $5.4B+30.0% | $4.2B-13.0% | $4.8B+1.0% | $4.8B+7.6% | $4.4B+10.4% | $4.0B+10.5% | $3.6B-4.3% | $3.8B |
| Interest Expense | $1.4B | $1.4B+18.3% | $1.2B+15.0% | $1.0B+21.0% | $851.0M+6.6% | $798.0M+1.8% | $784.0M+5.1% | $746.0M-0.9% | $753.0M+1.9% | $739.0M+2.2% | $723.0M+10.7% | $653.0M+8.7% | $600.7M-0.3% | $602.7M+17.8% | $511.8M+18.9% | $430.3M |
| Income Tax | $915.0M | $1.0B-45.7% | $1.9B+12.1% | $1.7B+0.7% | $1.7B-7.3% | $1.8B+10.8% | $1.7B+41.4% | $1.2B-10.6% | $1.3B+989.3% | $121.0M-94.2% | $2.1B+0.7% | $2.1B+14.5% | $1.8B+49.9% | $1.2B-0.1% | $1.2B-7.9% | $1.3B |
| Net Income | $5.0B | $5.7B-5.3% | $6.0B-0.1% | $6.0B+1.6% | $5.9B-4.3% | $6.2B+34.7% | $4.6B-4.9% | $4.8B+28.2% | $3.8B-2.4% | $3.8B+55.6% | $2.5B-3.5% | $2.6B-0.4% | $2.6B+3.2% | $2.5B-6.2% | $2.7B+0.3% | $2.6B |
| EPS (Diluted) | — | $25.21-1.8% | $25.68+1.8% | $25.22+3.9% | $24.28-2.7% | $24.95+38.8% | $17.98-2.7% | $18.47+30.2% | $14.19-1.1% | $14.35+55.8% | $9.21-1.8% | $9.38+4.3% | $8.99+9.6% | $8.20+0.2% | $8.18+12.8% | $7.25 |
Not reported in any period shown, so not listed: Gross Profit, R&D Expenses.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ELV Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $121.5B+3.9% | $116.9B+7.3% | $108.9B+6.0% | $102.8B+5.4% | $97.5B+12.5% | $86.6B+11.8% | $77.5B+8.2% | $71.6B+1.5% | $70.5B+8.4% | $65.1B+5.5% | $61.7B+0.1% | $61.7B+3.5% | $59.6B+1.1% | $59.0B+13.0% | $52.2B |
| Current Assets | $63.0B+6.9% | $58.9B-1.8% | $60.0B+7.9% | $55.6B+8.8% | $51.1B+11.7% | $45.8B+17.2% | $39.0B+13.7% | $34.3B-5.4% | $36.3B+5.7% | $34.3B+11.2% | $30.9B-3.4% | $31.9B+7.4% | $29.7B+1.4% | $29.3B+8.3% | $27.1B |
| Cash & Equivalents | $9.5B+14.5% | $8.3B+27.0% | $6.5B-11.7% | $7.4B+51.4% | $4.9B-15.0% | $5.7B+16.3% | $4.9B+25.5% | $3.9B+9.0% | $3.6B-11.4% | $4.1B+92.9% | $2.1B-1.8% | $2.2B+36.0% | $1.6B-36.1% | $2.5B+12.4% | $2.2B |
| Goodwill | $28.3B+0.2% | $28.3B+11.7% | $25.3B+3.8% | $24.4B+0.6% | $24.2B+11.7% | $21.7B+5.8% | $20.5B0.0% | $20.5B+6.6% | $19.2B+9.5% | $17.6B0.0% | $17.6B+2.8% | $17.1B+1.0% | $16.9B+0.2% | $16.9B+21.9% | $13.9B |
| Total Liabilities | $77.5B+2.7% | $75.5B+8.5% | $69.5B+4.7% | $66.4B+8.4% | $61.3B+14.7% | $53.4B+16.8% | $45.7B+6.3% | $43.0B-2.3% | $44.0B+10.1% | $40.0B+3.4% | $38.7B+3.3% | $37.4B+7.5% | $34.8B-1.0% | $35.2B+21.7% | $28.9B |
| Current Liabilities | $41.0B+1.1% | $40.6B-2.9% | $41.8B+5.3% | $39.7B+13.8% | $34.9B+18.4% | $29.5B+25.2% | $23.5B+7.1% | $22.0B-6.0% | $23.4B+9.7% | $21.3B+11.5% | $19.1B+1.8% | $18.8B+14.7% | $16.4B+2.2% | $16.0B+0.6% | $15.9B |
| Long-Term Debt | $30.8B+5.4% | $29.2B+25.7% | $23.2B+4.0% | $22.3B+5.6% | $21.2B+9.4% | $19.3B+8.7% | $17.8B+3.3% | $17.2B-0.9% | $17.4B+21.1% | $14.4B-6.3% | $15.3B+9.3% | $14.0B+3.3% | $13.6B-4.2% | $14.2B+67.4% | $8.5B |
| Total Equity | $43.9B+6.2% | $41.3B+5.1% | $39.3B+8.5% | $36.2B+0.4% | $36.1B+8.7% | $33.2B+4.6% | $31.7B+11.2% | $28.5B+7.7% | $26.5B+5.6% | $25.1B+8.9% | $23.0B-5.0% | $24.3B-2.1% | $24.8B+4.0% | $23.8B+2.2% | $23.3B |
| Retained Earnings | $35.4B+5.5% | $33.5B+5.7% | $31.7B+7.1% | $29.6B+9.2% | $27.1B+14.0% | $23.8B+5.4% | $22.6B+12.9% | $20.0B+10.7% | $18.1B+9.0% | $16.6B+12.1% | $14.8B+5.5% | $14.0B+1.5% | $13.8B+9.2% | $12.6B+10.1% | $11.5B |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable.
ELV Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $7.5B | $4.3B-26.1% | $5.8B-27.9% | $8.1B-4.0% | $8.4B+0.4% | $8.4B-21.7% | $10.7B+76.3% | $6.1B+58.4% | $3.8B-8.6% | $4.2B+28.0% | $3.3B-22.4% | $4.2B+25.0% | $3.4B+10.4% | $3.1B+11.2% | $2.7B-18.7% | $3.4B |
| Capital Expenditures | $1.2B | $1.1B-11.1% | $1.3B-3.1% | $1.3B+12.5% | $1.2B+6.0% | $1.1B+6.5% | $1.0B-5.2% | $1.1B-10.8% | $1.2B+52.7% | $791.0M+35.4% | $584.0M-8.5% | $638.2M-10.7% | $714.6M+10.5% | $646.5M+18.6% | $544.9M+4.9% | $519.5M |
| Free Cash Flow | $6.3B | $3.2B-30.3% | $4.6B-32.7% | $6.8B-6.7% | $7.2B-0.4% | $7.3B-24.7% | $9.7B+94.0% | $5.0B+90.3% | $2.6B-22.8% | $3.4B+26.4% | $2.7B-24.8% | $3.6B+34.6% | $2.7B+10.3% | $2.4B+9.4% | $2.2B-23.0% | $2.9B |
| Investing Cash Flow | -$2.2B | -$1.3B+74.0% | -$5.2B+7.3% | -$5.6B-22.2% | -$4.6B+52.7% | -$9.6B-31.6% | -$7.3B-162.3% | -$2.8B-121.8% | -$1.3B+75.2% | -$5.1B-888.7% | -$514.0M+55.4% | -$1.2B-18.1% | -$974.9M+56.4% | -$2.2B+50.9% | -$4.6B-383.2% | -$942.0M |
| Financing Cash Flow | -$3.5B | -$1.7B-245.7% | $1.2B+135.6% | -$3.3B-154.1% | -$1.3B-411.6% | $423.0M+116.5% | -$2.6B-13.3% | -$2.3B-1.1% | -$2.2B-624.8% | $427.0M+153.4% | -$799.0M+74.2% | -$3.1B-69.7% | -$1.8B-6.1% | -$1.7B-182.2% | $2.1B+203.5% | -$2.0B |
| Dividends Paid | $1.5B | $1.5B+1.4% | $1.5B+8.1% | $1.4B+13.5% | $1.2B+11.3% | $1.1B+15.7% | $954.0M+16.6% | $818.0M+5.4% | $776.0M+10.1% | $705.0M+3.1% | $684.0M+4.2% | $656.6M+36.6% | $480.7M+7.3% | $448.0M+22.0% | $367.1M+2.6% | $357.8M |
| Share Buybacks | $2.7B | $2.6B-10.2% | $2.9B+8.4% | $2.7B+15.5% | $2.3B+21.9% | $1.9B-29.6% | $2.7B+58.7% | $1.7B+0.9% | $1.7B-15.7% | $2.0B | $0-100.0% | $1.5B-49.5% | $3.0B+85.1% | $1.6B-35.1% | $2.5B-17.9% | $3.0B |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ELV Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 3.6%-0.8pp | 4.4%-0.5pp | 5.0%-0.3pp | 5.3%-0.2pp | 5.5%+0.2pp | 5.2%-0.5pp | 5.8%-0.1pp | 5.9%+1.3pp | 4.6%-1.0pp | 5.7%-0.3pp | 6.0%0.0pp | 6.0%+0.3pp | 5.6%-0.3pp | 5.9%-0.3pp | 6.2% |
| Net Margin | 2.8%-0.5pp | 3.4%-0.1pp | 3.5%-0.3pp | 3.8%-0.7pp | 4.4%+0.7pp | 3.8%-0.9pp | 4.6%+0.5pp | 4.1%-0.2pp | 4.3%+1.4pp | 2.9%-0.3pp | 3.2%-0.2pp | 3.5%0.0pp | 3.5%-0.8pp | 4.3%0.0pp | 4.4% |
| Return on Equity | 12.9%-1.6pp | 14.5%-0.8pp | 15.2%-1.0pp | 16.3%-0.8pp | 17.1%+3.3pp | 13.8%-1.4pp | 15.2%+2.0pp | 13.1%-1.4pp | 14.5%+4.7pp | 9.8%-1.3pp | 11.1%+0.5pp | 10.6%+0.5pp | 10.1%-1.1pp | 11.2%-0.2pp | 11.4% |
| Return on Assets | 4.7%-0.5pp | 5.1%-0.4pp | 5.5%-0.2pp | 5.7%-0.6pp | 6.3%+1.0pp | 5.3%-0.9pp | 6.2%+1.0pp | 5.2%-0.2pp | 5.5%+1.7pp | 3.8%-0.4pp | 4.2%0.0pp | 4.2%0.0pp | 4.2%-0.3pp | 4.5%-0.6pp | 5.1% |
| Current Ratio | 1.54+0.1x | 1.450.0x | 1.440.0x | 1.40-0.1x | 1.47-0.1x | 1.55-0.1x | 1.66+0.1x | 1.560.0x | 1.55-0.1x | 1.610.0x | 1.62-0.1x | 1.70-0.1x | 1.820.0x | 1.83+0.1x | 1.70 |
| Debt-to-Equity | 0.700.0x | 0.71+0.1x | 0.590.0x | 0.620.0x | 0.590.0x | 0.580.0x | 0.560.0x | 0.60-0.1x | 0.66+0.1x | 0.57-0.1x | 0.67+0.1x | 0.580.0x | 0.550.0x | 0.60+0.2x | 0.36 |
| FCF Margin | 1.6%-1.0pp | 2.6%-1.4pp | 4.0%-0.7pp | 4.6%-0.6pp | 5.3%-2.7pp | 7.9%+3.1pp | 4.8%+1.9pp | 2.8%-0.9pp | 3.8%+0.6pp | 3.2%-1.3pp | 4.5%+0.9pp | 3.6%+0.2pp | 3.4%-0.2pp | 3.6%-1.1pp | 4.7% |
Not reported in any period shown, so not listed: Gross Margin.
Similar Companies
Where Elevance Health Inc Ranks
Frequently Asked Questions
What is Elevance Health Inc's annual revenue?
Elevance Health Inc (ELV) reported $199.1B in total revenue for fiscal year 2025. This represents a 12.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Elevance Health Inc's revenue growing?
Elevance Health Inc (ELV) revenue grew by 12.5% year-over-year, from $177.0B to $199.1B in fiscal year 2025.
Is Elevance Health Inc profitable?
Yes, Elevance Health Inc (ELV) reported a net income of $5.7B in fiscal year 2025, with a net profit margin of 2.8%.
What is Elevance Health Inc's EBITDA?
Elevance Health Inc (ELV) had EBITDA of $8.7B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Elevance Health Inc have?
As of fiscal year 2025, Elevance Health Inc (ELV) had $9.5B in cash and equivalents against $30.8B in long-term debt.
What is Elevance Health Inc's operating margin?
Elevance Health Inc (ELV) had an operating margin of 3.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Elevance Health Inc's net profit margin?
Elevance Health Inc (ELV) had a net profit margin of 2.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Elevance Health Inc's return on equity (ROE)?
Elevance Health Inc (ELV) has a return on equity of 12.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Elevance Health Inc's free cash flow?
Elevance Health Inc (ELV) generated $3.2B in free cash flow during fiscal year 2025. This represents a -30.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Elevance Health Inc's operating cash flow?
Elevance Health Inc (ELV) generated $4.3B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Elevance Health Inc's total assets?
Elevance Health Inc (ELV) had $121.5B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Elevance Health Inc's capital expenditures?
Elevance Health Inc (ELV) invested $1.1B in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Elevance Health Inc's current ratio?
Elevance Health Inc (ELV) had a current ratio of 1.54 as of fiscal year 2025, which is generally considered healthy.
What is Elevance Health Inc's debt-to-equity ratio?
Elevance Health Inc (ELV) had a debt-to-equity ratio of 0.70 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Elevance Health Inc's return on assets (ROA)?
Elevance Health Inc (ELV) had a return on assets of 4.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Elevance Health Inc's Altman Z-Score?
Elevance Health Inc (ELV) has an Altman Z-Score of 3.14, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Elevance Health Inc's Piotroski F-Score?
Elevance Health Inc (ELV) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Elevance Health Inc's earnings high quality?
Elevance Health Inc (ELV) has an earnings quality ratio of 0.76x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Elevance Health Inc cover its interest payments?
Elevance Health Inc (ELV) has an interest coverage ratio of 5.13x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Elevance Health Inc?
Elevance Health Inc (ELV) scores 50 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.